Next Article in Journal
Polysaccharide-Rich Fraction of Noni Fruit (Morinda citrifolia L.) as Doxorubicin Co-Chemotherapy: Evaluation of Catalase, Macrophages, and TCD8+ Lymphocytes
Previous Article in Journal
Cost-Effective Isolation of a Process Impurity of Pregabalin
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Sci. Pharm.
Volume 83
Issue 3
10.3797/scipharm.1502-04
scipharm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Competent and Commercially Viable Process for the Synthesis of the Anti-Hypertensive Drug Olmesartan Medoxomil

by
Bommena HANUMANTHA RAO
1,2,*,
Inti Venkata SUBRAMANYESWARA RAO
1,
Vysyaraju RAVI KANTH
1,
Korrapati Venkata Vara PRASADA RAO
1,
K. BALAMURALI KRISHNA
2 and
Bethanabatla SYAMA SUNDAR
2,*
1
Chemical Research and Development, Aurobindo Pharma Pvt Ltd, Survey No. 71& 72, Indrakaran Village, Sangareddy Mandal, Medak District, Telangana-502329, India
2
Department of Chemistry, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur District, Andhra Pradesh-522510, India
*
Authors to whom correspondence should be addressed.
Sci. Pharm. 2015, 83(3), 465-478; https://doi.org/10.3797/scipharm.1502-04
Submission received: 15 February 2015 / Accepted: 31 March 2015 / Published: 31 March 2015
Versions Notes

Abstract

Drug product purity and potency are of most significance in the regulatory market as we notice many recalled batches worldwide, particularly in the US and Japan. Olmesartan Medoxomil is an anti-hypertensive drug. The present invention relates to a process for the preparation of Olmesartan Medoxomil with 99.9% purity in an overall 62% yield. The synthesis includes three isolations and one purification with easy plant operations. This process describes the formation and control of each individual impurity in all stages. This process for Olmesartan Medoxomil and its intermediates is competent for industrial production in very short reaction time intervals with an appreciable yield and high purity.
Keywords: Olmesartan medoxomil; Process Development; Impurities; Synthesis; Anti-hypertensive Drug Olmesartan medoxomil; Process Development; Impurities; Synthesis; Anti-hypertensive Drug

Share and Cite

MDPI and ACS Style

HANUMANTHA RAO, B.; SUBRAMANYESWARA RAO, I.V.; RAVI KANTH, V.; PRASADA RAO, K.V.V.; BALAMURALI KRISHNA, K.; SYAMA SUNDAR, B. A Competent and Commercially Viable Process for the Synthesis of the Anti-Hypertensive Drug Olmesartan Medoxomil. Sci. Pharm. 2015, 83, 465-478. https://doi.org/10.3797/scipharm.1502-04

AMA Style

HANUMANTHA RAO B, SUBRAMANYESWARA RAO IV, RAVI KANTH V, PRASADA RAO KVV, BALAMURALI KRISHNA K, SYAMA SUNDAR B. A Competent and Commercially Viable Process for the Synthesis of the Anti-Hypertensive Drug Olmesartan Medoxomil. Scientia Pharmaceutica. 2015; 83(3):465-478. https://doi.org/10.3797/scipharm.1502-04

Chicago/Turabian Style

HANUMANTHA RAO, Bommena, Inti Venkata SUBRAMANYESWARA RAO, Vysyaraju RAVI KANTH, Korrapati Venkata Vara PRASADA RAO, K. BALAMURALI KRISHNA, and Bethanabatla SYAMA SUNDAR. 2015. "A Competent and Commercially Viable Process for the Synthesis of the Anti-Hypertensive Drug Olmesartan Medoxomil" Scientia Pharmaceutica 83, no. 3: 465-478. https://doi.org/10.3797/scipharm.1502-04

Article Metrics

Back to TopTop